Pulmozym - mucolytic agent. It is a phosphorylated glycosylated recombinant deoxyribonuclease I, or dornase alpha, identical to the human DNase isolated from human urine. Dornase alpha is a genetically engineered version of the natural human enzyme that cleaves extracellular DNA.
The accumulation of a viscous purulent secretion in the respiratory tract plays a role in impaired respiratory function and in exacerbations of the infectious process in patients with cystic fibrosis. The purulent secretion contains very high concentrations of extracellular DNA, a viscous polyanion released from decaying white blood cells that accumulate as a result of the infection. In vitro, dornase alfa hydrolyzes DNA in sputum and markedly reduces sputum viscosity in cystic fibrosis.
Indications
To improve respiratory function in patients with cystic fibrosis over the age of 5 years, with an FVC index of at least 40% of the norm.
Pulmozyme can be used to treat patients with certain chronic lung diseases (bronchiectasis, chronic obstructive pulmonary disease, congenital lung malformations in children, chronic pneumonia, immunodeficiency conditions with lung damage, etc.), if the doctor estimates the mucolytic effect of dornase alpha benefits to patients.
Composition
1 vial (2.5 ml) of the solution for inhalation contains:
active substance: Dornase Alfa 2.5 mg
Excipients: sodium chloride, calcium chloride dihydrate, water for injection.
